Parents allege that the specialized, cow’s-milk based products for preterm infants caused ... against the formula companies, ...

(Bloomberg) -- Abbott Laboratories and a unit of Reckitt Benckiser ... consistent with years of studies that found its preterm baby formula was safe. The verdict reinforces the idea “there ...

after winning a favorable ruling from a U.S. court in connection with a premature baby formula lawsuit. A jury cleared Reckitt’s unit Mead Johnson and Abbott Laboratories (ABT) of allegations ...

Ron Wyden, D-Ore., is questioning Abbott Laboratories' business practices after the shutdown of one of the company's plants exacerbated the baby formula shortage in the U.S. While the U.S. is ...

In the closing of the recent trading day, Abbott (ABT) stood at $114.14, denoting a -1.18% change from the preceding trading day.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

On Monday, Abbott Laboratories, the biggest US supplier of powder infant formula brands such as Similac, reached a deal with regulators on steps needed to restart production at a key Michigan factory.

infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United ...

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products ...

The U.S. is in the midst of a panic-inducing baby formula shortage, and parents nationwide are struggling to get their kids the nutrition they need. Here's everything you need to know: Why is ...

Abbott (ABT) is one of the stocks most watched ... Shares of this maker of infant formula, medical devices and drugs have returned +3.8% over the past month versus the Zacks S&P 500 composite's ...